Rare diseases
Investigational molecules
Locations
Study comparing two forms of cagrilintide with placebo for weight loss in adults with overweight or obesity
GreeceA study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity
AustriaA study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease
BulgariaA study testing cagrilintide and semaglutide combination for kidney damage in people with chronic kidney disease and type 2 diabetes who are overweight or obese
FranceA Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity
AustriaStudy on the Effectiveness of NNC0194-0499 and Semaglutide in Treating Non-Alcoholic Steatohepatitis (NASH) in Patients with Fibrosis Stages 2-4
BelgiumWeight loss in adults with obesity (with or without type 2 diabetes) using cagrilintide and semaglutide: a study of two dose levels versus semaglutide alone
AustriaStudy comparing cagrilintide and semaglutide versus tirzepatide in people with type 2 diabetes taking metformin or SGLT2 inhibitor
GermanyA study testing NNC0194-0499, cagrilintide, and semaglutide alone or combined to treat liver damage in people with alcohol-related liver disease
BulgariaA study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin
BulgariaA study testing cagrilintide and semaglutide compared to placebo in people with type 2 diabetes not well controlled by diet and exercise
HungaryA study testing cagrilintide for weight loss in people with overweight or obesity and type 2 diabetes
CroatiaTell us about your condition – we search every trial in Europe and connect you with the right site.
